ABZYME THERAPEUTICS LLC
Last verified 2026-05-06. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.7Mattributed |
|---|---|
| Latest round | grant, $1.7M, 2024-01-01attributed |
| Founded | 2017 |
| Headquarters | Pottstown, Pennsylvania, USA |
| Industry | healthtech |
| Stage | unknown |
| Website | abzymetx.com |
Abzyme Therapeutics develops modular single-domain VHH antibody fragments for immunotherapy using a proprietary yeast-display discovery platform. It serves biopharma partners needing antibodies optimized for affinity, solubility, and developability. Its differentiator is a self-diversifying library that screens these properties in real time.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | grant | $1.7M | undisclosed |
Detected tech stack
Cloudflare, WordPress, Genesis theme, Slider Revolution 6.7.55, jQuery Migrate 3.4.1, WP Rocket, PHP, MySQL, jquery 3.
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $1.7M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $1.7M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | abzymetx.com, read 2026-05-06 |
| Description | self-reported | abzymetx.com, read 2026-05-06 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.